Pharmaceuticals

MSI-H And dMMR Market 2025–2029: Strategic Opportunities and Growth Insights

December 4, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the msi-h and dmmr market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The MSI-H And dMMR Market Now And By 2029?

The market for MSI-H and dMMR has seen rapid expansion in recent years. It is projected to grow from $6.15 billion in 2024 to $7.57 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 23.0%. This historic growth can be attributed to several factors including a rising incidence of colorectal and endometrial cancers, expanded genetic screening programs, increasing clinical adoption of MSI testing, greater awareness of hereditary cancer syndromes, and a rise in the use of liquid biopsy.

The market size for MSI-H and dMMR is predicted to undergo substantial growth in the forthcoming years. It is forecast to expand to $17.26 billion in 2029, achieving a compound annual growth rate (CAGR) of 22.9%. The increase during this projected period can be attributed to several factors, including a heightened demand for personalized cancer therapies, the expanding applications of next-generation sequencing, increased healthcare expenditure in oncology, the proliferation of clinical trials for immune checkpoint inhibitors, and robust regulatory support for companion diagnostics. Significant trends anticipated over the forecast period involve the integration of artificial intelligence into diagnostic workflows, strategic partnerships between pharmaceutical and diagnostic companies, the evolution of multiplex biomarker panels, advancements in immunotherapy, and a notable shift towards pan-cancer biomarker testing.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Long-Term Drivers Are Expected To Sustain The MSI-H And dMMR Market?

The increasing occurrence of cancer is projected to drive expansion in the MSI-H and dMMR market moving forward. Cancer constitutes a set of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. The growing incidence of cancer is largely attributed to aging demographics, given that the likelihood of developing cancer markedly rises with advancing age due to the combined impact of genetic alterations and extended exposure to risk factors over a period. In cancer treatment, MSI-H and dMMR serve to pinpoint tumors exhibiting elevated mutation rates stemming from deficiencies in DNA repair systems. These biological markers aid in directing immunotherapy choices, since these particular tumors show a greater propensity to react to immune checkpoint inhibitors, while also offering clarity on prognosis and potential inherited conditions. As an illustration, in January 2024, the American Cancer Society, a US-based non-profit organization, reported that for 2023, approximately 1,958,310 new cancer diagnoses and 609,820 cancer-related fatalities were anticipated in the United States. These figures are projected to climb in 2024, with around 2,001,140 new cancer cases and 611,720 deaths foreseen, underscoring an ongoing upward trend in cancer occurrence and fatality. Consequently, the increasing prevalence of cancer is stimulating the expansion of the MSI-H and dMMR market.

How Is The MSI-H And dMMR Market Classified By Different Segments?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Current And Upcoming Trends Are Shaping The MSI-H And dMMR Market?

Major companies active in the MSI-H and dMMR market are concentrating on developing innovative treatments, such as combination therapy, to boost treatment effectiveness and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves utilizing two or more treatment modalities, commonly immunotherapy agents like checkpoint inhibitors, or integrating immunotherapy with chemotherapy, targeted therapy, or radiation. This strategy aims to enhance treatment response, overcome resistance, and improve survival rates in patients whose tumors display high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical company, secured United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) characteristics, further progressing treatment alternatives for this difficult cancer subtype. This approval signifies a key milestone in the management of MSI-H and dMMR cancers, offering a new, effective therapeutic choice that targets multiple pathways to improve patient survival and response rates, thereby addressing the unmet medical needs in this patient population.

Who Are The Primary Market Leaders In The MSI-H And dMMR Market?

Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Regional Markets Are Emerging As Key Centers For The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2025, By The Business Research Company

Dna And Gene Chip Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-and-gene-chip-global-market-report

Dna Based Skin Care Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-based-skin-care-products-global-market-report

Dna Digital Data Storage Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-digital-data-storage-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795